Company profile
OPKO HEALTH, INC.
NASDAQ:OPKBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SOMATROGON | phase3 | — | 8 | completed, terminated |
| LUNACALCIPOL | phase2 | — | 2 | no active trials |
| PEGAPAMODUTIDE | phase2 | — | 2 | completed, terminated |
| SCYLLO-INOSITOL | phase2 | — | 5 | completed, terminated |
| TT-301 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (53)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01766336 | phase2 | terminated | 2013-01-01 | 2015-08-01 | OPKO Health, Inc. | A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease |
| NCT01791725 | phase2 | completed | 2013-09-01 | 2014-06-01 | OPKO Health, Inc. | A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia |
| NCT03810664 | phase1 | completed | 2019-01-18 | 2019-04-19 | OPKO Health, Inc. | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations |
| NCT01909479 | phase3 | terminated | 2013-06-01 | 2016-08-01 | OPKO Health, Inc. | A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency |
| NCT02919800 | phase1 | completed | 2017-01-22 | 2018-02-21 | OPKO Health, Inc. | A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male |
FDA applications (0)
No records yet.